Overall, the p53 gene was associated with increased risk for invasive cervical cancer. However, the risk varied by country, cellular, and HPV type.

No abstract

BackgroundSome studies have investigated the effects of polymorphisms in the vascular endothelial growth factor (VEGF) gene on responsiveness to chemotherapy for colorectal cancer (CRC) and have shown inconclusive results.MethodsEligible studies that assessed the associations between polymorphisms in the VEGF gene and response to chemotherapy in CRC were searched in the PubMed, Embase and Medline databases until November 2014. Odds ratios (OR) and 95% confidence intervals (CIs) were used to evaluate the associations, using Review Manager software, version 5.3. Stratified analysis was also conducted.ResultsIn the overall analysis, a significant association with responsiveness to chemotherapy in CRC was identified in CC vs. CA of the VEGF -2578 C/A polymorphism (OR = 1.40, 95% CI 1.00-1.97, P = 0.05) and in CC+CT vs. TT of the VEGF -460 C/T polymorphism (OR = 0.71, 95% CI 0.53-0.96, P = 0.02). In subgroup analysis, a significant association was found in excluding anti-angiogenic agent subgroup in three comparison models of the VEGF -2578 C/A polymorphism and another three genetic models of the VEGF -460 C/T C/A polymorphism.ConclusionsCC vs. CA of the VEGF -2578 C/A polymorphism and CC+CT vs. TT of the VEGF -460 C/T polymorphism might be predictive factors of responsiveness to chemotherapy in CRC. However, single-nucleotide polymorphisms in the VEGF gene lacked sufficient predictive ability to determine whether patients with CRC should add anti-angiogenic agents to their chemotherapy regimens.

Background:The effects of the vascular endothelial growth factor (VEGF) gene −2578C/A polymorphism on colorectal cancer (CRC) risk have been investigated in some studies; however, the results of these studies were conflicting and ambiguous. Therefore, we aimed to do a meta-analysis to investigate the association of VEGF −2578C/A polymorphisms with CRC risk from all eligible case-control studies published to date.Materials and Methods:An electronic search of the PubMed, Embase and Medline was performed. Retrieve terms were utilized as following: (“VEGF a” [MeSH Terms]) and (“polymorphism, genetic” [MeSH Terms]) and (“colorectal neoplasms” [MeSH Terms]). The association between VEGF −2578C/A polymorphisms with CRC risk was calculated with odds ratios (ORs) and their corresponding 95% of confidence intervals (CIs), and stratified analysis was also conducted with respect to ethnicity.Results:A comprehensive meta-analysis of eight studies, including 2312 cases and 2308 controls was performed in this work. Combined analysis revealed that a significant association between the VEGF −2578C/A polymorphism with CRC risk was identified in three comparison models including C allele versus A allele (OR = 0.85, 95% CI 0.75-0.97, P = 0.02), AA versus CA + CC (OR = 1.28, 95% CI 1.09-1.51, P = 0.003), and AA versus CC (OR = 0.77, 95% CI 0.64-0.93, P = 0.006). Moreover, a similar result was obtained in the subgroup analysis that comparison models of C allele versus. A allele (OR = 0.85, 95% CI 0.76-0.95, P = 0.004), AA versus CA + CC (OR = 1.31, 95% CI 1.09-1.57, P = 0.004), and AA versus CC (OR = 0.73, 95% CI 0.59-0.90, P = 0.004) was confirmed to be associated with CRC risk in Caucasian.Conclusion:It has been proved that the C allele versus A allele, AA versus CA + CC, and AA versus CC comparison models of VEGF −2578C/A polymorphism might be risk factors for CRC, but further studies with larger sample sizes are required to make a better assessment of above association.

No abstract